This information is for healthcare professionals, however not intended for UK or Ireland audience.
Are you a healthcare professional (not UK or Ireland)?
About Waylivra
Waylivra is an antisense oligonucleotide designed to inhibit the translation of apoC-III (1)
Waylivra Mode of Action
By reducing ApoC-III*, Waylivra removes an inhibitor of triglyceride clearance, enabling triglyceride metabolism through an LPL-independent pathway in patients with FCS.1
* Apolipoprotein C-III (ApoC-III) modulates triglyceride levels primarily by inhibiting the LPL-dependent pathway but also the LPL-independent pathway.
APPROACH STUDY RESULTS
Waylivra significantly reduced fasting triglycerides1
When added to diet, Waylivra delivered a 77 % mean reduction in fasting triglycerides at 3 months and maintained statically significant reductions for a full year.1
Waylivra led to a lower incidence of pancreatitis1,2
An analysis of patients with a history of recurrent pancreatitis events (≥ 2 events in the 5 years prior to Study Day 1) showed a significant reduction in pancreatitis attacks in Waylivra-treated patients compared to placebo-treated patients (p=0.0242).1
Pancreatitis attacks* during the 52-week study period:
- in the Waylivra group: none of the 7 patients who had 24 pancreatitis attacks* in the 5 years prior to study enrollment, experienced an attack.
- in the placebo group: 3 of the patients who had 17 pancreatitis attacks* in the prior 5 years, experienced 4 attacks.
OPEN-LABEL EXTENSION STUDY RESULTS
Results support the long-term use of Waylivra in patients with FCS3
The OLE-study* evaluated long-term Waylivra treatment in 62 patients** with FCS and showed:
Sustained efficacy up to 156 weeks
Consistent safety profile up to 156 weeks with previously published studies
The results of the OLE-study support the long-term use of Waylivra in adult patients with genetically confirmed FCS at high risk for pancreatitis in conjunction with diet
* This study had some limitations, including those inherent with an open-label study design. Without a placebo or non-treatment group, assessing whether an actual reduction in acute pancreatitis risk occurred is challenging.
** Confirmation of FCS type I phenotype–based on disease history, PCR, or next-generation sequencing results.
Safety
Waylivra safety profile1
| System organ class | Very common reactions (≥1/10) | Common reactions (≥1/100 to <1/10) |
|---|---|---|
| Blood and lymphatic system disorders | Thrombocytopenia | Leukopenia, lymphopenia, eosinophilia, immune thrombocytopenic purpura, spontaneous haematoma |
| Immune system disorders | Immunisation reaction, hypersensitivity, serum sickness-like reaction | |
| Metabolism and nutrition disorders | Diabetes mellitus | |
| Psychiatric disorders | Insomnia | |
| Nervous system disorders | Headache | Syncope, hypoaesthesia, presyncope, retinal migraine, dizziness, tremor |
| Eye disorders | Conjunctival haemorrhage, vision blurred | |
| Vascular disorders | Haematoma, hypertension, haemorrhage, hot flush | |
| Respiratory, thoracic, and mediastinal disorders | Dyspnoea, pharyngeal oedema, wheezing, epistaxis, cough, nasal congestion | |
| Gastrointestinal disorders | Nausea, diarrhoea, vomiting, abdominal distension, abdominal pain, dry mouth, gingival bleeding, mouth haemorrhage, parotid gland enlargement, dyspepsia, gingival swelling | |
| Skin and subcutaneous tissue disorders | Erythema, pruritus, rash, urticaria, hyperhidrosis, petechiae, ecchymosis, night sweats, papule, skin hypertrophy, swelling face | |
| Musculoskeletal and connective tissue disorders | Myalgia | Arthralgia, pain in extremity, arthritis, musculoskeletal pain, back pain, neck pain, pain in jaw, muscle spasms, joint stiffness, myositis, peripheral arthritis |
| Renal and urinary disorders | Haematuria, proteinuria | |
| General disorders and administration site conditions | Injection site erythema, injection site pain, injection site swelling, injection site discolouration, injection site induration, injection site pruritus, injection site bruising, chills, injection site oedema | Injection site haematoma, asthenia, fatigue, injection site reaction, pyrexia, injection site hypoaesthesia, injection site haemorrhage, injection site warmth, injection site dryness, injection site pallor, injection site urticaria, injection site vesicles, malaise, feeling hot, influenza-like illness, injection site discomfort, injection site inflammation, injection site mass, oedema, pain, injection site paraesthesia, injection site scab, injection site papule, injection site rash, non-cardiac chest pain, vessel puncture site haemorrhage |
| Investigations | Platelet count decreased | Haemoglobin decreased, white blood cell count decreased, blood creatinine increased, blood urea increased, creatinine renal clearance decreased, hepatic enzyme increased, international normalised ratio increased, transaminases increased |
| Injury, poisoning, and procedural complications | Contusion |
The most common adverse reactions reported in the APPROACH trial were injection-site reactions and decreased platelet count including thrombocytopenia.2
Platelet monitoring
Platelet monitoring is necessary during treatment1
- Prior to initiation of Waylivra, patients should have a platelet count ≥140 × 109/L
- During treatment, platelet levels should be monitored at least every 2 weeks and dosing and frequency of monitoring modified according to the table below
| Platelet count (× 109/L) | Dose (285 mg prefilled syringe) | Monitoring frequency |
|---|---|---|
| Normal ≥140 | Starting dose: Weekly. After 3 months: Every 2 weeks |
Every 2 weeks |
| 100 to 139 | Every 2 weeks | Weekly |
| 75 to 99 | Pause treatment for ≥4 weeks and resume treatment after platelet levels ≥100 x 109/L | Weekly |
| 50 to 74a | Pause treatment for ≥4 weeks and resume treatment after platelet levels ≥100 × 109/L | Every 2-3 days |
| <50a,b | Discontinue treatment. Glucocorticoids recommended | Daily |
a. Discontinuation of antiplatelet medicinal products/NSAIDs/anticoagulants should be considered for platelet levels <75 × 109/L. Treatment with these medicinal products must be discontinued at platelet levels <50 × 109/L.1
b. Consultation of a haematologist is needed to reconsider the benefit/risk for possible further treatment with Waylivra in a patient who has discontinued due to severe thrombocyotpenia (<50 x 109/L).1
References
- Waylivra ® SmPC, Nov 2022.
- Witztum JL et al. Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome. N Engl J Med. 2019 Aug 8;381(6):531-542. doi: 10.1056/NEJMoa1715944. PMID: 31390500.
- Witzum JL et al., Journal of Clinical Lipidology (2023) 000, 1–14 Published: March 21, 2023. DOI:https://doi.org/10.1016/j.jacl.2023.03.007